Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
  1. Predictions
buy

Fate Therapeutics Inc. buy Barclays PLC

Fate Therapeutics Inc.
Start price
€6.42
27.02.24 / 50%
Target price
€9.22
27.02.25
Performance (%)
-81.86%
End price
€1.16
28.02.25
Summary
This prediction ended on 28.02.25 with a price of €1.16. Massive losses of -81.86% were the result for the BUY prediction by Barclays_PLC. Barclays_PLC has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Fate Therapeutics Inc. 14.057% 14.057% 187.378%
iShares Core DAX® 2,57 % 3,50 % 8,41 %
iShares Nasdaq 100 4,86 % 0,65 % 28,38 %
iShares Nikkei 225® 5,59 % -0,25 % 52,92 %
iShares S&P 500 3,25 % 2,08 % 24,37 %

Comments by Barclays_PLC for this prediction

In the thread Fate Therapeutics Inc. diskutieren
Prediction Buy
Perf. (%) -81.86%
Target price 9.222
Change
Ends at 27.02.25

Fate Therapeutics, Inc. (NASDAQ: FATE) had its price target raised by analysts at Barclays PLC from $6.00 to $10.00. They now have an "overweight" rating on the stock.
Ratings data for FATE provided by MarketBeat

Barclays PLC 
0
Report Share
27.02.24
In the thread Trading Fate Therapeutics Inc.
Prediction Buy
Perf. (%) -81.86%
Target price 9.222
Change
Ends at 27.02.25

Die von Barclays_PLC gewählte maximale Laufzeit wurde überschritten

Barclays PLC 
0
Report Share
28.02.25

Stopped prediction by Barclays_PLC for Fate Therapeutics Inc.

buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€0.86
14.05.25
€1.79
14.05.26
79.27%
15.05.26

Barclays PLC 
14.05.25 50%